All In Biotech

Drug Trial Radar · NCT06786234

A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

An Open-Label, Phase 2 Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 18, 2025

Primary completion

Jun 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Step Pharma, SASIndustry
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are: * Does STP938 control platelet counts * Does STP938 control platelet counts without inducing unwanted side effects Participants will: * Take STP938 every day for up to 12 months. * Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests. * Complete a questionnaire about symptoms once a month.

Conditions

  • Essential Thrombocythaemia

Interventions

  • STP938Drug

    At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical EfficacyTime frame: Through study completion, an average of 12 months
  2. Safety and TolerabilityTime frame: Through study completion, an average of 12 months

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • CHU Brest

    Brest, France · Recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU Nice

    Nice, France · Recruiting

  • CHU Nîmes

    Nîmes, France · Recruiting

  • Hôpital Saint-Louis

    Paris, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Hôpital de la Milétrie, CHU

    Poitiers, New Aquitaine, France · Not yet recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • Imperial College London / Hammersmith Hospital

    London, United Kingdom · Recruiting

  • Sarah Cannon Research Institute

    London, United Kingdom · Recruiting

  • Cancer and Haematology Centre, Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • University of Southampton Hospital

    Southampton, United Kingdom · Recruiting

  • Royal Hallamshire Hospital

    Sheffield, South Yorkshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.